An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM); shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival.